# QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma

> **NCT07049185** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 35 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** QL1706 Plus Celecoxib Group

## Key facts

- **NCT ID:** NCT07049185
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07049185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07049185, "QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07049185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*